Previous close | 17.64 |
Open | 17.92 |
Bid | 18.29 x 1000 |
Ask | 18.31 x 1100 |
Day's range | 17.74 - 18.75 |
52-week range | 8.86 - 32.48 |
Volume | 2,002,041 |
Avg. volume | 2,782,998 |
Market cap | 1.009B |
Beta (5Y monthly) | 0.89 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.70 |
Earnings date | 23 Jun 2021 - 28 Jun 2021 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 14 Oct 1999 |
1y target est | 18.75 |
Rite Aid's (RAD) Q4 results gain from RxEvolution strategy, strength in Elixir brand and robust online growth. However, COVID-related costs woes and lesser cases of cough, cold and flu are concerns.
RAD earnings call for the period ending March 31, 2021.
Rite Aid Corporation (NYSE: RAD) today reported operating results for its fourth quarter and fiscal year ended February 27, 2021.